AstraZeneca’s Gout Drug Zurampic Clears FDA; Renal, CV Safety Trial Required
Executive Summary
Label includes box warning on acute renal failure risk.
You may also be interested in...
Keeping Track: New Indication For Lucentis; New Lesinurad Application From Ironwood
The latest drug development news and highlights from our FDA Performance Tracker.
Companies Reveal Hurdles In Providing Drugs Via Expanded Access Programs
GSK, Stealth BioTherapeutics and Blueprint Medicines discuss the difficulties getting participation of physicians, the excessive cost of expanded access, and whether physicians should report research data.
Current Pathways For Rare Disease Drugs Are Not Optimal, US FDA’s Califf Says
Anticipating a ‘tsunami of therapies’ for rare diseases, commissioner says the agency will have to think of creative approaches and employ regulatory flexibility for them. FDA considers copying the oncology center’s Project Facilitate for expanded access to other diseases.